Thomas Albini, MD
Retina Specialist · Miami, FLNPI 1831106079
Payments from drug & device makers
Across 281 payments — averaging $1000.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$94K
- Eyepoint US, Inc.$42K
- Apellis Pharmaceuticals, Inc.$39K
- Bausch & Lomb Americas Inc.$23K
- AbbVie$20K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$18K
- plus $44K from 24 others
Across 8 payments — averaging $5447.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis Pharma AG$33K
- Novartis$10K
What the payments were for
- Consulting fees$232,82983%
- Speaking & faculty fees$28,78910%
- Travel & lodging$6,0052%
- Food & beverage$13,5395%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 29 | $93,619 |
| Eyepoint US, Inc. | 41 | $42,037 |
| Apellis Pharmaceuticals, Inc. | 25 | $39,493 |
| Bausch & Lomb Americas Inc. | 40 | $23,364 |
| AbbVie(2 entities) | 29 | $20,053 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 18 | $18,245 |
| Beaver-visitec International, Inc. | 3 | $16,500 |
| Genentech USA, Inc. | 11 | $5,606 |
| Regeneron | 5 | $4,611 |
| Pfizer | 2 | $4,295 |
| Alimera Sciences, Inc. | 15 | $4,002 |
| Mallinckrodt Enterprises LLC | 4 | $3,841 |
| ANI Pharmaceuticals, Inc. | 6 | $1,842 |
| Astellas Pharma US Inc | 13 | $1,017 |
| Alcon | 9 | $1,013 |
| Regeneron Healthcare Solutions, Inc. | 13 | $389 |
| Genentech, Inc. | 3 | $338 |
| Notal Vision, Inc. | 1 | $286 |
| Carl Zeiss Meditec, Inc. | 3 | $167 |
| Astellas Pharma Global Development | 1 | $110 |
| Dutch Ophthalmic, USA | 1 | $74 |
| Resmed Corp | 1 | $61 |
| Samsara Vision | 1 | $35 |
| Harrow Eye, LLC | 1 | $33 |
| Neurotech Pharmaceuticals, Inc. | 1 | $32 |
| Biogen | 1 | $28 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $25 |
| Dompe US, Inc. | 1 | $22 |
| Rxsight Inc | 1 | $17 |
| Aerie Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BEOVU$82,793
- YUTIQ$41,399
- XIPERE$38,639
- Syfovre$23,293
- DUREZOL$9,042
- OZURDEX$6,782
- Lucentis$5,086
- VELSIPITY$4,295
- ACTHAR$3,750
- Iluvien$3,688
- EYP-1901$1,850
- PURIFIED CORTROPHIN GEL$1,700
- DEXYCU$1,039
- Constellation$516
- SUSVIMO$459
- ForeseeHome$286
- Izervay$269
- VYZULTA$214
- ACTIVEFOCUS$147
- AcrySof$147
How this compares
$281,164 in reported general payments places this provider in the 85th percentile of 118 retina specialist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 66 | $445,967 |
| RestasisCyclosporine | 50 | $33,114 |
| Prednisolone Acetate | 619 | $32,801 |
| XiidraLifitegrast | 24 | $15,704 |
| Difluprednate | 64 | $10,167 |
| Restasis MultidoseCyclosporine | 16 | $8,818 |
| Mycophenolate Mofetil | 81 | $6,705 |
| ValacyclovirValacyclovir Hcl | 135 | $6,464 |
| LumiganBimatoprost | 14 | $5,406 |
| Tacrolimus | 24 | $3,950 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 230 | $3,600 |
| Loteprednol Etabonate | 16 | $3,457 |
| Ketorolac Tromethamine | 95 | $3,398 |
| Atropine Sulfate | 66 | $3,087 |
| Alphagan PBrimonidine Tartrate | 11 | $2,567 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Restasis Multidose, Lumigan, Alphagan P | $20,053 | $49,90491 claims |
| Bausch & Lomb Americas Inc.Xiidra | $23,364 | $15,70424 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $18,245 | $3,45716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 118 retina specialist providers in Florida.
Other retina specialist in Miami
- Zohar YehoshuaMiami$402K
- Philip RosenfeldMiami$293K
- Audina BerrocalMiami$210K
- Hong-Uyen HuaMiami$85K
- Justin TownsendMiami$76K
- Nicolas YannuzziMiami$60K
- Harry FlynnMiami$7K
- Shailesh GuptaDeerfield Beach$18.8M
- Vrinda HershbergerMelbourne$8.2M
- Sunil GuptaPensacola$8.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.